If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
=== Children === In most countries, fluoroquinolones are only approved for use in children under narrowly defined circumstances, owing in part to the observation of high rates of musculoskeletal adverse events in fluoroquinolone-treated juvenile animals. The use of fluoroquinolones in those 18 years of age and under is only FDA approved for complicated UTI's (pyelonephritis and for postexposure prophylaxis) and treatment of inhalation anthrax. In the UK, the prescribing indications for fluoroquinolones for children are severely restricted. Only inhalational anthrax and pseudomonal infections in cystic fibrosis infections are licensed indications in the UK due to ongoing safety concerns. In a study comparing the safety and efficacy of levofloxacin to that of azithromycin or ceftriaxone in 712 children with community-acquired pneumonia, serious adverse events were experienced by 6% of those treated with levofloxacin and 4% of those treated with comparator antibiotics. Most of these were considered by the treating physician to be unrelated or doubtfully related to the study drug. Two deaths were observed in the levofloxacin group, neither of which was thought to be treatment-related. Spontaneous reports to the U.S. FDA Adverse Effects Reporting System at the time of the 20 September 2011 U.S. FDA Pediatric Drugs Advisory Committee included musculoskeletal events (39, including five cases of tendon rupture) and central nervous system events (19, including five cases of seizures) as the most common spontaneous reports between April 2005 and March 2008.
=== Possible health risks === Some evidence suggests that T. molitor may pose a health risk, as humans and animals can consume the eggs and larvae of the beetle with grain-based food. Although they are usually either digested or are excreted with feces, sometimes, they are able to survive and live in the alimentary tract. The first cases of T. molitor larvae in human organs date back to the 19th century, where their presence was observed in the gastrointestinal tract, including the stomach and intestines. There were other cases, such as a reported ulcer infestation of T. molitor in an AIDS patient and a concerned urinary canthariasis in a ten-year-old boy in Iran in 2019, which was the last reported human case of canthariasis caused by T. molitor. However, there are very few reported cases of live larvae in animals, and there are no reports of gastrointestinal canthariasis in farm animals. A study analysing the results of patients in Poland for the presence of specific IgE antibodies to the mealworm was conducted prior to its widespread introduction as a food ingredient. Sensitisation to the mealworm was detected in 4.3% of the patients, with monosensitisation occurring rarely and affecting 0.7% of this group. It was determined that the presence of antibodies to the mealworm most often co-occurs with sensitization to other edible insects, such as the house cricket and the migratory locust, as well as to tropomyosins from shrimp and house dust mites. The primary or cross-sensitization may differ in different populations depending on the dietary habits or geographical zone.
Under Wenger, Arsenal reached their first UEFA Champions League final in 2006 and relocated from Highbury to the Emirates Stadium. Financial constraints following the move contributed to a nine-year trophy drought, though Wenger later guided the club to further FA Cup victories in the 2010s, becoming the competition's most successful manager with seven wins. He stepped down as Arsenal manager in 2018 and retired from club management. Wenger is credited with reshaping English football culture and modernising the managerial profession, though his teams were occasionally criticised for tactical naivety and disciplinary issues. Wenger is also noted for his emphasis on youth development and talent identification throughout his career.
Sources: en.wikipedia.org
=== Physiology === Rhabdomyolysis causes the myosin and actin to degenerate into smaller proteins that travel into the circulatory system. The body reacts by increasing intracellular swelling to the injured tissue to send repair cells to the area. This allows creatine kinase and myoglobin to be flushed from the tissue where it travels in the blood until reaching the kidneys. In addition to the proteins released, large quantities of ions such as intracellular potassium, sodium, and chloride find their way into the circulatory system. Intracellular potassium ion has deleterious effects on the heart's ability to generate action potentials leading to cardiac arrhythmias. Consequently, this can affect peripheral and central perfusion which in turn can affect all major organ systems in the body. When the protein reaches the kidneys it causes a strain on the anatomical structures reducing its effectiveness as a filter for the body. The protein acts as a dam as it forms into tight aggregates when it enters the renal tubules. In addition, the increased intracellular calcium has greater time to bind due to the blockage allowing for renal calculi to form. As a result this causes urine output to decrease allowing for the uric acid to build up inside the organ. The increased acid concentration allows the iron from the aggregate protein to be released into the surrounding renal tissue. Iron then strips away molecular bonds of the surrounding tissue which eventually will lead to kidney failure if the tissue damage is too great.
The number of the union republics of the USSR varied from 4 to 16. From 1956 until its dissolution in 1991, the Soviet Union consisted of 15 Soviet Socialist Republics: in 1956, the Karelo-Finnish Soviet Socialist Republic, created in 1940, was absorbed into the Russian Soviet Federative Socialist Republic. Rather than listing the republics in alphabetical order, the republics were listed in constitutional order (which roughly corresponded to their population and economic power when the republics were formed). However, particularly by the last decades of the Soviet Union, the constitutional order did not correspond to order either by population or economic power.
The NADP+ structural site is located greater than 20Å away from the substrate binding site and the catalytic coenzyme NADP+ binding site. Its purpose in the enzyme catalyzed reaction has been unclear for many years. For some time, it was thought that NADP+ binding to the structural site was necessary for dimerization of the enzyme monomers. However, this was shown to be incorrect. On the other hand, it was shown that the presence of NADP+ at the structural site promotes the dimerization of dimers to form enzyme tetramers. It was also thought that the tetramer state was necessary for catalytic activity; however, this too was shown to be false. The NADP+ structural site is quite different from the NADP+ catalytic coenzyme binding site, and contains the nucleotide-binding fingerprint. The structural site bound to NADP+ possesses favorable interactions that keep it tightly bound. In particular, there is a strong network of hydrogen bonding with electrostatic charges being diffused across multiple atoms through hydrogen bonding with four water molecules (see figure). Moreover, there is an extremely strong set of hydrophobic stacking interactions that result in overlapping π systems.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.